Qomel Company Limited (TADAWUL:9600)

Revenue by Segment

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Sale of Medicines and Medical Products	132.23M	124.20M	105.47M	77.71M	61.23M
Sale of Medicines and Medical Products Growth	6.46%	17.76%	35.72%	26.93%	-
Total	132.23M	124.20M	105.47M	77.71M	61.23M
Total Growth	6.46%	17.76%	35.72%	26.93%	-

Revenue by Geography

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Kingdom of Saudi Arabia	132.23M	124.20M	105.47M	77.71M	61.23M
Kingdom of Saudi Arabia Growth	6.46%	17.76%	35.72%	26.93%	-
Total	132.23M	124.20M	105.47M	77.71M	61.23M
Total Growth	6.46%	17.76%	35.72%	26.93%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 2, 2026

Data Sources Report a data error